Mehmet Kaplan1, Fethi Yavuz2, Gizem Ilgın Kaplan3, Nurbanu Bursa4, Ertan Vuruşkan1, Murat Sucu1. 1. Department of Cardiology, Faculty of Medicine, Gaziantep University; Gaziantep-Turkey. 2. Department of Cardiology, Adana City Training and Research Hospital; Adana-Turkey. 3. Department of Internal Medicine, Ersin Arslan Training and Research Hospital; Gaziantep-Turkey. 4. Department of Statistics, Hacettepe University; Ankara-Turkey.
Abstract
OBJECTIVE: Worldwide, over 200 million people are diagnosed with lower extremity arterial disease (LEAD). LEAD significantly increases the risk of death and amputation of the lower limb. A new classification system (WIfI) has been proposed to initially assess all patients with ischemic rest pain or wounds and also predicts 1-year amputation risk. Elabela is a bioactive peptide and a part of the apelinergic system, which has beneficial effects on body fluid homeostasis and cardiovascular health. We aimed to investigate serum Elabela levels in LEAD. METHODS: A total of 119 subjects were enrolled in this cross-sectional study, 60 of whom were in the LEAD group and 59 in the control group. All participants underwent physical examination and routine biochemical tests, including serum Elabela levels. Additionally, the LEAD group was divided into subgroups according to the Rutherford classification, ankle-brachial index (ABI) values, and WIfI risk scores. RESULTS: Serum low-density lipoprotein, Elabela, and high-sensitivity C-reactive protein (Hs-CRP) levels were statistically higher in the LEAD group (p=0.002, p<0.001, and p<0.001, respectively). In the Rutherford classification, as the stage increased, Elabela and Hs-CRP levels increased similarly (p<0.001). Elabela levels were statistically found to be positively correlated with Hs-CRP and WIfI amputation score but negatively correlated with ABI (p<0.001). CONCLUSION: Serum Elabela level, which is known to be increased in inflammatory processes, has the potential in predicting low extremity arterial obstruction and WIfI amputation risk in LEAD patients.
OBJECTIVE: Worldwide, over 200 million people are diagnosed with lower extremity arterial disease (LEAD). LEAD significantly increases the risk of death and amputation of the lower limb. A new classification system (WIfI) has been proposed to initially assess all patients with ischemic rest pain or wounds and also predicts 1-year amputation risk. Elabela is a bioactive peptide and a part of the apelinergic system, which has beneficial effects on body fluid homeostasis and cardiovascular health. We aimed to investigate serum Elabela levels in LEAD. METHODS: A total of 119 subjects were enrolled in this cross-sectional study, 60 of whom were in the LEAD group and 59 in the control group. All participants underwent physical examination and routine biochemical tests, including serum Elabela levels. Additionally, the LEAD group was divided into subgroups according to the Rutherford classification, ankle-brachial index (ABI) values, and WIfI risk scores. RESULTS: Serum low-density lipoprotein, Elabela, and high-sensitivity C-reactive protein (Hs-CRP) levels were statistically higher in the LEAD group (p=0.002, p<0.001, and p<0.001, respectively). In the Rutherford classification, as the stage increased, Elabela and Hs-CRP levels increased similarly (p<0.001). Elabela levels were statistically found to be positively correlated with Hs-CRP and WIfI amputation score but negatively correlated with ABI (p<0.001). CONCLUSION: Serum Elabela level, which is known to be increased in inflammatory processes, has the potential in predicting low extremity arterial obstruction and WIfI amputation risk in LEAD patients.
Authors: L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes; Kevin Bell; Joseph Caporusso; Isabelle Durand-Zaleski; Kimihiro Komori; Johannes Lammer; Christos Liapis; Salvatore Novo; Mahmood Razavi; Johns Robbs; Nicholaas Schaper; Hiroshi Shigematsu; Marc Sapoval; Christopher White; John White; Denis Clement; Mark Creager; Michael Jaff; Emile Mohler; Robert B Rutherford; Peter Sheehan; Henrik Sillesen; Kenneth Rosenfield Journal: Eur J Vasc Endovasc Surg Date: 2006-11-29 Impact factor: 7.069
Authors: James C Simpkin; Derek M Yellon; Sean M Davidson; Shiang Y Lim; Abigail M Wynne; Christopher C T Smith Journal: Basic Res Cardiol Date: 2007-08-13 Impact factor: 17.165
Authors: Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais Journal: Eur Heart J Date: 2018-09-01 Impact factor: 29.983
Authors: Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais Journal: Eur Heart J Date: 2018-03-01 Impact factor: 29.983
Authors: Ábel Perjés; Teemu Kilpiö; Johanna Ulvila; Johanna Magga; Tarja Alakoski; Zoltán Szabó; Laura Vainio; Eveliina Halmetoja; Olli Vuolteenaho; Ulla Petäjä-Repo; István Szokodi; Risto Kerkelä Journal: Basic Res Cardiol Date: 2015-11-26 Impact factor: 17.165
Authors: Gareth D Barnes; Shirjel Alam; Gordon Carter; Christian M Pedersen; Kristina M Lee; Thomas J Hubbard; Scott Veitch; Herim Jeong; Audrey White; Nicholas L Cruden; Les Huson; Alan G Japp; David E Newby Journal: Circ Heart Fail Date: 2013-03-21 Impact factor: 8.790